Comparative study of safety and efficacy of oral betamethasone pulse therapy and azathioprine in vitiligo

Background: Vitiligo is a common skin disorder causing depigmented macules that can impair a patient's quality of life. There are number of treatment modalities are available but at the present, there are no studies compairing betamethasone pulse therapy versus azathioprine daily therapy in treatment of vitiligo. Objectives: To compare the safety and efficacy of Azathioprine daily and Betamethasone pulse therapy in the treatment of in vitiligo. Materials and Methods: We included two vitiligo patient groups. namely group A and group B Patients of group A were given oral Azathioprine to be given 50mg twice daily and those of second group B, Betamethasone were given as a single oral dose of 5 mg on two consecutive days per week. Therapy in both groups was given for a total of 6months with follow up at 1, 3 and 6th month. Clinical photographs were taken at each visit. Side-effects if any were noted. Results were calculated with help of VASI score (vitiligo area severity index). Results: At the baseline: The patients to group A (SD 3.81± 2.3) and of group B (SD 3.76± 2.28) were having depigmented patches (P = 0.90). At the first follow up: Although there was significant improvement with perifollicular repigmentation started in both groups but the patients are of group B (SD 3.38±2.06) were showing slower response as compared to oral group A (SD 3.70± 2.28). At the second follow up: Remarkable improvement is seen in both groups compared (P = 0.17). At the third follow up: Significant improvement is seen in both groups compared (P = 0.09). Conclusions: Azathioprine and betamethasone pulse therapy are equally effective in treatment of vitiligo.

[1]  C. Terwee,et al.  Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo , 2015, The British journal of dermatology.

[2]  M. Picardo,et al.  Epidemiology, Definitions and Classification , 2010 .

[3]  D. Khan,et al.  CHILDHOOD VITILIGO: RESPONSE TO METHYLPREDNISOLONE ORAL MINIPULSE THERAPY AND TOPICAL FLUTICASONE COMBINATION , 2009, Indian journal of dermatology.

[4]  G. Hautmann,et al.  Vitiligo: a psychologically influenced and influencing disease. , 1997, Clinics in dermatology.

[5]  F. Flowers,et al.  AZATHIOPRINE: A FORGOTTEN ALTERNATIVE FOR TREATMENT OF SEVERE PSORIASIS , 1992, International journal of dermatology.

[6]  Callen Jp,et al.  Azathioprine: effective steroid-sparing therapy for generalized lichen planus. , 1992 .

[7]  J. Pasricha,et al.  Evaluation of Five Different Regimes For the Treatment of Vitiligo. , 1989, Indian journal of dermatology, venereology and leprology.

[8]  D. Canafax,et al.  The Therapeutic Use of Azathioprine in Renal Transplantation , 1987, Pharmacotherapy.

[9]  S. Ajit,et al.  A Clinical Study of Vitiligo. , 1977, Indian journal of dermatology, venereology and leprology.

[10]  K. Thomsen,et al.  Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. , 1977, Archives of dermatology.

[11]  H. Tagami,et al.  Treatment of vitiligo with oral corticosteroids. , 1976, Dermatologica.

[12]  L. Juhlin,et al.  IMMUNOGLOBULIN E IN “HEALED” ATOPIC DERMATITIS AND AFTER TREATMENT WITH CORTICOSTEROIDS AND AZATHIOPRINE , 1970, The British journal of dermatology.

[13]  I. Chanarin,et al.  VITILIGO AND ITS AETIOLOGICAL RELATIONSHIP TO ORGAN‐SPECIFIC AUTOIMMUNE DISEASE , 1969, The British journal of dermatology.